CVS Health Option Alert: Fri $50 Calls Sweep (6) near the Bid: 350 vs 7628 OI

CVS Health Option Alert: Fri $50 Calls Sweep (6) near the Bid: 350 @ $15.3 vs 7628 OI; Ref=$65.26

CVS Health Option Alert: Mar 21 $52.5 Calls at the Ask: 500 vs 5506 OI

CVS Health Option Alert: Mar 21 $52.5 Calls at the Ask: 500 @ $14.3 vs 5506 OI; Ref=$66.475

CVS Health Option Alert: Jan, 2026 $65 Puts at the Bid: 2000 vs 5799 OI

CVS Health Option Alert: Jan, 2026 $65 Puts at the Bid: 2000 @ $6.65 vs 5799 OI; Ref=$66.23

CVS Health Option Alert: Jun 20 $52.5 Calls at the Bid: 2950 vs 4662 OI

CVS Health Option Alert: Jun 20 $52.5 Calls at the Bid: 2950 @ $13.2 vs 4662 OI; Ref=$64.59

CVS Health Option Alert: Jan, 2026 $52.5 Calls at the Bid: 5001 vs 5445 OI

CVS Health Option Alert: Jan, 2026 $52.5 Calls at the Bid: 5001 @ $15.2 vs 5445 OI; Ref=$64.7

CVS Health Option Alert: Jan, 2026 $47.5 Calls at the Bid: 4000 vs 4284 OI

CVS Health Option Alert: Jan, 2026 $47.5 Calls at the Bid: 4000 @ $18.0 vs 4284 OI; Ref=$64.255

CVS Health (NYSE:CVS) 주식

CVS HEALTH CORP

CVS Health

CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 27 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all existing business lines.

Jim Cramer

Earnings

Equities

News

Markets

General

AAPL

AMZN

MSFT

SBUX

SPOT

CNBC의 짐 크레이머가 주요 기술 기업의 실적 발표와 주요 경제 업데이트로 가득한 또 다른 한 주를 투자자들에게 준비시키고 있다.지난 금요일(25일) 짐 크레이머는 이번 주 투자자들이 애플(NASDAQ:AAPL), 아마존(NASDAQ:AMZN), 메타 플랫폼스(NASDAQ:META), 마이크로소프트(NASDAQ:MSFT)의 실적 발표에 대비해야 한다고 강조했다. 또한 이번 주에는 중요한 경제 지표들도 함께 발표될 것이라고 CNBC가 보도했다.

짐 크레이머, 관세 혼란 속 주요 기술 기업 실적 발표에 대비하라 경고

wall street ai15

Education

Econ #s

VRTX

2025년 1분기에 가장 성과가 좋았던 S&amp;P 500 주식 다섯 종목은 CVS 헬스(NYSE:CVS), 필립모리스(NYSE:PM), 뉴몬트(NYSE:NEM), 센코라(NYSE:COR), 그리고 버텍스 파마슈티컬스(NASDAQ:VRTX)이며, 이들은 최근 며칠 동안 단지 미미한 하락만 겪었다. 무역 긴장과 경기 침체에 대한 우려로 S&amp;P 500 지수가 10% 급락한 것과는 대조적이다. 

S&amp;P 500 종목 중 2025년 1분기에 강세 보인 5개 주식...랠리 지속될까?

Health Care

Technicals

Signals

Tech

Trading Ideas

CVS 헬스(NYSE:CVS)의 주식이 골든 크로스를 완성하며 강세 신호를 보이고 있다. 골든 크로스는 50일 단순 이동 평균(SMA)이 200일 SMA를 상향 돌파할 때 발생한다. 주식이 연초 이후 51% 이상 상승하고 주요 이동 평균선 위에서 거래되고 있는 가운데, 기술적 분석은 추가 상승을 시사한다.

CVS 헬스 주식, 체중 감량 프로그램의 대 성과로 골든 크로스 형성

CVS Health Corp

Morgan Stanley ETF Trust Calvert Ultra-Short Investment Grade ETF

CARDIOVASCULAR SCI INC by Cardiovascular Sciences, Inc.

Morgan Stanley ETF Trust Calvert US Select Equity ETF

CVS Group PLC

CIVITAS SOCIAL HSG PLC by CIVITAS SOCIAL HSG PLC

CV Sciences Inc

COVISTA COMMUNS INC by Covista Communications, Inc,

Covista Communications Inc

CONVERGENCE SYS INC CL A by Convergence Systems Inc.

Convergence Systems Inc

President Donald Trump on Monday signed a sweeping executive order aimed at drastically reducing prescription <a href="https://www.benzinga.com/topic/drug-prices">drug prices in the U.S. </a>
What Happened: The Trump administration wants to tie drug prices to the lowest amount paid in comparable foreign countries — a policy known as <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45381118/cvs-health-cigna-stocks-dip-tuesday-whats-going-on">&#8220;most-favored-nation&#8221; pricing.</a>
The executive order is <a href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-announces-actions-to-put-american-patients-first-by-lowering-drug-prices-and-stopping-foreign-free-riding-on-american-pharmaceutical-innovation/">a response</a> to what Trump described as &#8220;unreasonable or discriminatory&#8221; practices abroad. 
"In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism aboard [abroad] with skyrocketing prices at home," Trump said in <a href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-announces-actions-to-put-american-patients-first-by-lowering-drug-prices-and-stopping-foreign-free-riding-on-american-pharmaceutical-innovation/">a statement</a>.&nbsp;
Drug manufacturers have 30 days to voluntarily lower prices for prescription drugs in the U.S. to match those paid in other advanced nations.&nbsp;
If companies do not comply, the Department of Health and Human Services, led by Robert F. Kennedy Jr., is tasked with developing rules to enforce most-favored nation (MFN) pricing or other regulatory measures.&nbsp;
The HHS is also instructed to establish mechanisms for Americans to purchase drugs directly from manufacturers at the MFN price, bypassing pharmacy benefit managers (PBMs) and other intermediaries.&nbsp;
Read Next: <a href="https://www.benzinga.com/25/05/45378427/trump-wants-to-kickstart-nuclear-development-these-5-stocks-could-boom?utm_source=articleShare">Trump Wants To Kickstart Nuclear Development: These 5 Stocks Could Boom</a>&nbsp;
Why It Matters: The executive order is a rare show of common ground between the Trump administration and Democratic leaders like Senator Bernie Sanders, who has long fought for laws aimed at making medicine more affordable.
And Trump has tried this before. During his first term, he signed a similar <a href="https://trumpwhitehouse.archives.gov/presidential-actions/executive-order-lowering-drug-prices-putting-america-first-2/">order</a> that the courts ultimately blocked after the pharmaceutical industry lobbied against it.
Sanders fears the same thing might happen again. In a <a href="https://bsky.app/profile/did:plc:upw5n2uwhzubjajdtqaufsek/post/3loyh44tra225?ref_src=embed&amp;ref_url=https%253A%252F%252Fwww.commondreams.org%252Fnews%252Ftrump-executive-order-drug-prices">post</a> on the Bluesky social network, he agreed that it is &#8220;an outrage that the American people pay, by far, the highest prices in the world for prescription drugs.&#8221;
&#8220;As Trump well knows, his executive order will be thrown out by the courts,&#8221; said Sanders. &#8220;If Trump is serious about making real change rather than just issuing a press release, he will support legislation I will soon be introducing to make sure we pay no more for prescription drugs than people in other major countries. If Republicans and Democrats come together on this legislation, we can get it passed in a few weeks.&#8221;
Pharmaceutical stocks dropped in Monday's premarket trading, but recovered into positive territory by the market close.
Analysts and investors decided the order was less-specific than feared and likely to be challenged in court.&nbsp;
"A drug pricing announcement had been expected for a while now and had weighed on stocks in this sector, so the official executive order doesn&#8217;t seem to be impacting sentiment too much,&#8221; said James Harlow, senior vice president at Novare Capital Management, per Reuters.&nbsp;
In contrast, Trump&#8217;s comments of &#8220;cutting out the middlemen&#8221; weighed on shares of companies that own pharmacy benefit managers like The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) and UnitedHeath Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>).&nbsp;
"I would cut out the middlemen," Trump said. "Everybody should equalize. Everybody should pay the same price."
Shares of UnitedHealth plunged Tuesday after<a href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance"> the company</a> pulled its 2025 outlook, citing that care activity continued to accelerate and CEO Andrew Witty unexpectedly resigned.&nbsp;
Read Next: <a href="https://www.benzinga.com/25/05/45354683/tesla-probably-wont-make-money-on-ride-hailing-for-years-gary-black-says?utm_source=articleShare">Tesla Robotaxi Hopes Dashed By Uber, Lyft: No Fast Lane To Profits, Warns Investor Gary Black&nbsp;</a>
What To Watch: The executive order threatens the PBM business model by enabling direct-to-consumer drug purchases, which could significantly reduce the need for PBMs&#8217; negotiating and administrative services. However, legal experts have raised concerns about the legality of direct-to-consumer sales.&nbsp;
"This order's suggestion of broader or direct-to-consumer importation stretches well beyond what the statute allows," warned health policy lawyer, Paul Kim, per the New York Post.&nbsp;
Investors in the healthcare sector may choose to mitigate risk and exposure to PBMs through a diversified healthcare ETF like the SPDR Select Health Care Sector Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) which holds shares of pharmaceuticals, health care equipment and supplies and health care providers.&nbsp;
An ETF like the iShares U.S. Medical Devices ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITI#NYSE">ITI</a>) which tracks the Dow Jones U.S. Select Medical Equipment Index and invests in leading U.S. medical device companies also offers exposure to the healthcare industry while reducing exposure to pharmaceutical benefit managers.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45319531/cathie-wood?utm_source=articleShare">Cathie Wood Says AI Will &#8216;Disrupt The Traditional World Order&#8217; And Replace Search Engines Like Google</a>&nbsp;</li>
</ul>
Image: Shutterstock

Large Cap

Sector ETFs

Specialty ETFs

Politics

Movers

ETFs

Trump Again Promises Lower Drug Prices By 'Cutting Out Middlemen' Like UnitedHealth, CVS: Will It Work This Time?

CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) and The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) shares trading lower Tuesday. President Donald Trump on Monday signed an executive order aimed at reducing the cost <a href="https://www.benzinga.com/24/12/42517567/cvs-cigna-unitedhealth-shares-slide-as-trump-targets-drug-middleman">of prescription drugs.</a>
What To Know: According to the Wall Street Journal, the executive order directs Health Secretary Robert F. Kennedy to coordinate with pharmaceutical companies over the next month to lower drug prices. It also directs both the U.S. Trade Representative and the Commerce Department to take steps to combat unreasonable and discriminatory policies in foreign countries.
The order essentially aims to tie U.S. drug prices to those paid by other countries, many of which pay less due to government-negotiated rates. Trump said the order equalizes costs, arguing that Americans have been subsidizing cheaper prices abroad.
It also allows for Kennedy to impose rules and restrictions on drug companies and imports, if the companies don&#8217;t lower prices within 180 days.
The order doesn't clarify whether the pricing changes would affect Medicare or Medicaid.
CVS owns CVS Caremark and Cigna owns Express Scripts, both of which operate as pharmacy benefit managers (PBM). Investors may be reacting to the executive order's potential to undercut PBM revenues by tying U.S. drug prices to international rates rather than prices negotiated by PBMs.
CVS and Cigna may also be under pressure after UnitedHealth <a href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance">suspended its guidance</a>, as investors consider whether the same factors could impact the broader industry.
Related Link: <a href="https://www.benzinga.com/25/05/45376610/xrp-price-surges-amid-bullish-technical-indicators-sees-more-institutional-adoption">XRP Price Surges Amid Bullish Technical Indicators, Sees More Institutional Adoption</a>
Price Action: At the time of writing, CVS shares are trading 4.83% lower at $61.73 and Cigna shares are trading 2.68% lower at $307.29, according to data from <a href="https://www.benzinga.com/pro/login">Benzinga Pro.</a>
Image: via Shutterstock

CVS Health, Cigna Stocks Dip Tuesday: What's Going On?

WIIM

ALHC

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

Shares of health insurance stocks are trading lower after UnitedHealth suspended its 2025 outlook as medical expenditures were expected to be larger than anticipated.

Financial giants have made a conspicuous bullish move on CVS Health. Our analysis of options history for CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) revealed 10 unusual trades.
Delving into the details, we found 40% of traders were bullish, while 40% showed bearish tendencies. Out of all the trades we spotted, 8 were puts, with a value of $329,770, and 2 were calls, valued at $201,958.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $63.0 to $70.0 for CVS Health during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for CVS Health options trades today is 2262.5 with a total volume of 4,453.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for CVS Health's big money trades within a strike price range of $63.0 to $70.0 over the last 30 days.
<h3>CVS Health Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747144863_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$1.37</td>
<td>$1.15</td>
<td>$1.27</td>
<td>$65.00</td>
<td>$126.5K</td>
<td>3.7K</td>
<td>1.0K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$2.16</td>
<td>$2.1</td>
<td>$2.15</td>
<td>$63.00</td>
<td>$87.0K</td>
<td>1.5K</td>
<td>704</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$1.31</td>
<td>$1.3</td>
<td>$1.3</td>
<td>$70.00</td>
<td>$75.4K</td>
<td>2.0K</td>
<td>107</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/30/25</td>
<td>$2.5</td>
<td>$2.31</td>
<td>$2.4</td>
<td>$63.00</td>
<td>$48.0K</td>
<td>1.5K</td>
<td>972</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$2.2</td>
<td>$2.15</td>
<td>$2.2</td>
<td>$63.00</td>
<td>$43.5K</td>
<td>1.5K</td>
<td>924</td>
</tr>
</tbody>
</table>

<h3>About CVS Health</h3>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 27 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all existing business lines.
After a thorough review of the options trading surrounding CVS Health, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is CVS Health Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 2,066,081, the CVS's price is down by -4.79%, now at $61.7. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 85 days.</li>
</ul>
<h3>Professional Analyst Ratings for CVS Health</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $80.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Truist Securities has decided to maintain their Buy rating on CVS Health, which currently sits at a price target of $84. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on CVS Health with a target price of $84. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for CVS Health, targeting a price of $71. 
&#x2A; An analyst from RBC Capital persists with their Outperform rating on CVS Health, maintaining a target price of $81. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on CVS Health with a target price of $82. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest CVS Health options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

CVS Health Options Trading: A Deep Dive into Market Sentiment

Truist Securities analyst David Macdonald maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Buy and raises the price target from $82 to $84.

Price Target

Analyst Ratings

Truist Securities Maintains Buy on CVS Health, Raises Price Target to $84

Shares of health insurance stocks and pharmacy benefit mangers are trading lower amid President Trump's executive order on drug pricing.

<a href="https://www.cnbc.com/2025/05/12/trump-drug-pricing-order-most-favored-nation.html">https://www.cnbc.com/2025/05/12/trump-drug-pricing-order-most-favored-nation.html</a>
&nbsp;
<ul>
<li>President Donald Trump will revive a controversial policy that aims to slash drug costs by tying the amount the government pays for some medicines to lower prices abroad, White House officials said.</li>
<li>The order is a blow to the pharmaceutical industry, which is already bracing for Trump&#39;s planned tariffs on prescription drugs.</li>
<li>It is Trump&#39;s latest effort to try to rein in U.S. prescription drug prices, which are two to three times higher on average than those in other developed nations.</li>
</ul>
&nbsp;

MRNA

'Trump To Sign Order To Cut Some U.S. Drug Prices To Match Those Abroad' - CNBC

One year ago, we established a concentrated position in shares of&nbsp;CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>). Since our purchases in May 2024,&nbsp;CVS shares have generated a total return of 25% reflecting initial progress in the long-term cultural and operational turnaround underway at the Company. &nbsp;Our position size afforded us the scale necessary to constructively engage with the Board, Management, and fellow Shareholders in Q3 2024 on a multi-faceted performance improvement plan:
<ol>
<li>Board Refreshment&nbsp;– The Board welcomed four new Directors including Larry Robbins, Glenview's CEO, and recently appointed a strong Lead Independent Director.&nbsp; The entire Board is operating cooperatively and cohesively; &nbsp;</li>
<li>Strengthening Culture and Leadership&nbsp;– CVS's leadership has undergone significant transformation under new CEO David Joyner's leadership, combining internal promotion with external recruitment while strengthening a customer-centric, accountable culture; &nbsp;</li>
<li>Operational Intensity&nbsp;– CVS exceeded consensus earnings expectations over the past two quarters and has seen operating strength and early signs of recovery across its businesses; &nbsp;</li>
<li>Risk Management&nbsp;– The Company has suspended material acquisitions, committed to deleveraging, strengthened its insurance reserve levels and established a clear path to sustainable returns on capital that will fuel future customer service and benefit stability; &nbsp;</li>
<li>Portfolio Enhancement and Innovation&nbsp;– CVS has exited or transitioned certain lines of business where economics prevent a sustainable commitment to customers while leading the industry with transparent and value-added solutions to reduce cost and complexity; and &nbsp;</li>
<li>Opportunistic Capital Deployment&nbsp;– In combination, CVS has marched closer to the time in which share repurchase can be both a responsible consideration and a creator of long-term shareholder value.&nbsp;</li>
</ol>
Following healthy Q1 results and increased annual guidance, Glenview reduced its overall holdings by 3.75 million shares consistent with our fund's diversification parameters and to create buying power for further unique opportunities in this volatile macro environment.&nbsp;With this rebalancing, CVS Health remains our largest position, and we have no plans for additional adjustments to our CVS holdings.&nbsp; Our confidence in the near, medium, and long-term outlook for CVS remains strong.&nbsp;
We are grateful for the engagement and enthusiasm of the entire CVS Health team in the revitalization efforts well underway and are fully committed to making continued contributions to the vitality and long-term success of this iconic institution that strengthens the health of 185 million people.
Together we grow.
&nbsp;

Management

Glenview Capital Issues Statement On CVS Health; Highlights 25% Return On CVS Health Investment Since May 2024 As Turnaround Gains Traction, Citing Board Refresh, Cultural And Leadership Overhaul Under New CEO, Operational Gains, Deleveraging, Strategic Business Exits, And Renewed Capital Discipline; Says CVS Remains Firm's Largest Holding After Modest Rebalancing

Wells Fargo analyst Stephen Baxter maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Overweight and raises the price target from $76 to $84.

Wells Fargo Maintains Overweight on CVS Health, Raises Price Target to $84

RBC Capital analyst Ben Hendrix maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Outperform and raises the price target from $74 to $81.

RBC Capital Maintains Outperform on CVS Health, Raises Price Target to $81

UBS analyst Kevin Caliendo maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Neutral and raises the price target from $67 to $71.

UBS Maintains Neutral on CVS Health, Raises Price Target to $71

In the last three months, 10 analysts have published ratings on CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $76.3, a high estimate of $82.00, and a low estimate of $71.00. Surpassing the previous average price target of $67.60, the current average has increased by 12.87%.
<img src="https://www.benzinga.com/files/images/story/2025/1746212421_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive CVS Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$82.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$71.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$76.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$74.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$73.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$73.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CVS Health. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CVS Health compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of CVS Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into CVS Health's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CVS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CVS Health analyst ratings.</a>
<h2>About CVS Health</h2>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 27 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all existing business lines.
<h3>CVS Health's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3M period, CVS Health showcased positive performance, achieving a revenue growth rate of 4.15% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CVS Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 1.68%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): CVS Health's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.18%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): CVS Health's ROA excels beyond industry benchmarks, reaching 0.65%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 1.1, CVS Health adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On CVS Health Through 10 Analysts

Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Canada unit on Thursday announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental new drug submission (sNDS) for semaglutide 2.4 mg, a once-weekly therapy for people living with MASH <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">(metabolic dysfunction-associated steatohepatitis)</a>.
&#8220;Semaglutide 2.4 mg represents a therapeutic advancement for patients living with MASH, addressing a critical unmet medical need,&#8221; <a href="https://www.newswire.ca/news-releases/health-canada-accepts-semaglutide-2-4-mg-a-glp-1ra-treatment-for-mash-as-a-supplemental-new-drug-submission-under-the-priority-review-policy-881682700.html#:~:text=Semaglutide%20injection%202.4%20mg%20is,%E2%89%A5%2027%20kg%2Fm2.&amp;text=Semaglutide%20is%20not%20approved%20in%20Canada%20for%20the%20treatment%20of%20MASH." target="_blank" rel="noreferrer noopener">says</a> Vince Lamanna, President of Novo Nordisk Canada Inc. &#8220;Health Canada&#8217;s acceptance of the Semaglutide 2.4 mg submission for review brings us one step closer to providing the first treatment option for eligible people living with MASH.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44934811/eli-lilly-positioned-to-dominate-obesity-market-with-oral-option-analyst-initiates-with-confidence" rel="noreferrer noopener">Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence</a>
In November 2024, Health Canada approved Wegovy (semaglutide injection) to <a href="https://www.novonordisk.ca/content/dam/nncorp/ca/en/press-releases/2024/wegovy-non-fatal-mi-indication-announcement-press-release-112624.pdf" target="_blank" rel="noreferrer noopener">reduce</a> the risk of non-fatal myocardial infarction (MI) in adults with established cardiovascular disease and a  BMI equal to or greater than 27 kg/m2.
It was the first Health Canada-approved treatment to support both chronic weight management and to reduce the risk of non-fatal MI.
MASH is a chronic, progressive metabolic disease affecting the liver.
Among people who are overweight or have obesity, about one in three also have MASH.
Excess fat can build up in the liver, which, over time, can lead to inflammation and severe scarring of the liver.
By 2030, the prevalence of MASH in the Canadian general population is estimated to increase from 5.2% to 6.5%.
In&nbsp;Canada, the number of deaths is expected to double in people living with MASH by 2030.
On Thursday, Novo Nordisk announced that&nbsp;CVS Health Inc's&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)&nbsp;CVS Caremark, a Pharmacy Benefit Manager (PBM), decided that Wegovy&nbsp;(semaglutide) injection 2.4 mg will soon be the preferred&nbsp;GLP-1&nbsp;medicine on its largest commercial&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45147328/cvs-caremark-to-place-novo-nordisks-wegovy-on-preferred-coverage-for-glp-1-weight-loss-treatment" rel="noreferrer noopener">template formularies</a>.
This change will take effect on&nbsp;July 1, 2025.&nbsp;
In February, the FDA confirmed that all doses of Wegovy were available. In March, Novo Nordisk launched NovoCare Pharmacy to provide direct-to-patient, convenient home shipments of all Wegovy dose strengths at a reduced cost of $499 per month for <a href="https://www.benzinga.com/25/03/44143391/novo-nordisk-boosts-wegovy-access-with-lower-pricing-and-home-delivery" target="_blank" rel="noreferrer noopener">self-paying patients</a>.
More recently, the Wegovy&nbsp;savings offer was updated, allowing eligible self-paying patients to get the&nbsp;$499-per-month price at their local pharmacy.
On Tuesday,&nbsp;Novo Nordisk and&nbsp;Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) announced a&nbsp;<a target="_blank" href="https://www.benzinga.com/25/04/45074872/hims-hers-stock-surges-as-it-collaborates-with-novo-nordisk-to-sell-weight-loss-drug-wegovy-on-its-platform" rel="noreferrer noopener">long-term collaboration</a>.
The company said that individuals may be prescribed Wegovy at a single, unified price starting at $599 per month. The offering is available this week on the Hims &amp; Hers platform.
This new offering builds on Hims &amp; Hers&#8217; existing suite of weight loss solutions and provides self-pay patients with access to all dose strengths of Wegovy in a high-quality pen.
Price Action: NVO stock is up 5.5% at $69.21at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45170554/dupont-delivers-strong-q1-highlights-electronics-spin-off-confirms-2025-guidance" target="_blank" rel="noreferrer noopener">DuPont Delivers Strong Q1, Highlights Electronics Spin-Off, Confirms 2025 Guidance</a></li>
</ul>
Photo: Shutterstock

Biotech

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Why Is Novo Nordisk Stock Trading Higher On Friday?

Barclays analyst Andrew Mok maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Overweight and raises the price target from $73 to $82.

Barclays Maintains Overweight on CVS Health, Raises Price Target to $82

Editor&#8217;s Note: The article has been udpated to correct the Stock Movers list.
Wall Street pushed higher in midday trading, with the S&amp;P 500 on track for its eighth consecutive gain — its longest winning streak since November 2023. The index rose about 1% to 5,560, fully recovering the losses sustained after former President Donald Trump announced <a href="https://www.benzinga.com/topic/tariffs">trade tariffs on April 2.</a>
Technology stocks led the rally, with the Nasdaq 100 climbing 1.5%. Strong and resilient corporate earnings continue to fuel investor appetite for risk, helping markets shrug off recent tariff concerns.
President Trump reassured investors, stating that progress on trade negotiations is going "very well" and that the timeline for the tax bill remains on schedule.
On the economic front, data continued to paint a weaker picture. After Wednesday's disappointing first-quarter GDP report, the ISM manufacturing PMI showed factory activity contracted for the second straight month in April. Meanwhile, price pressures surged at the fastest pace since June 2022, reflecting <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45139383/us-manufacturing-activity-contracts-in-april-as-tariffs-push-input-prices-toward-3-year-highs">inflationary effects from tariffs.</a>
Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>) was a standout gainer, soaring 8.60% after delivering a blowout quarter that beat expectations across the board, reinforcing its leadership in cloud and AI. The stock reached its highest level since late January.
Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) also topped estimates, with shares climbing more than 4%.
Sector-wise, technology outperformed, while health care lagged. Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) plunged over 9% after the pharmaceutical giant cut its 2025 guidance.
Crude oil erased early losses, rebounding to $58 per barrel after briefly dipping below $57. Gold slipped 2.2% to a two-week low.
The U.S. dollar strengthened to its highest level in over two weeks, bolstered by manufacturing surveys showing rising input costs tied to tariffs.
Treasury yields climbed for a second straight session, with the 10-year yield rising to 4.21%.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) surged past the $97,000 mark, hitting its highest level in over two months.
<h1 class="wp-block-heading">Thursday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>% chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,853.70</td>
<td>+ 1.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,614.89</td>
<td>+ 0.9%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,971.76</td>
<td>+ 0.4%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,802.25</td>
<td>+ 0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:55 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1% to $560.02.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.5% to $408.25.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 1.6% to $483.23.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.5% higher to $195.71.</li>
<li>The&nbsp;Technology&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 2.6%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 2.3%.</li>
</ul>
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
Stocks reacting to earnings reports included: Microsoft Corporation: up 8.30% Meta Platforms, Inc.: up 4.29% Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>): &#8211; 9.88% Mastercard Incorporated&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>): -0.20% McDonald's Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>): -1.24% Linde plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>): -1.14% Qualcomm Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>): -8.28% KKR &amp; Co. Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>): up 1.19% The Southern Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>): up 0.22% Intercontinental Exchange, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>): up 1.83% KLA Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>): -2.43% CVS Health Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>): up 6.23% Equinix, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>): -0.16% Parker-Hannifin Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>): up 0.70% Air Products and Chemicals, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>): -0.09% Howmet Aerospace Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>): up 7.44% Carrier Global Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>): up 11% Aflac Incorporated&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>): -4% Public Storage&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>): -0.18% The Allstate Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>): -1.27% MetLife, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>): up 0.47% W.W. Grainger, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>): Up 2.14% Becton, Dickinson and Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>): -15.73% Quanta Services, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>): up 10.10% Exelon Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>): -0.33% Dominion Energy, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>): up 0.91%
Stocks slated to report earnings after the bell include Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), Arthur J. Gallagher &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>), Airbnb Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>), Atlassian Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>), Motorola Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>), EOG Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>), American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>), Consolidated Edison Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>), Ingersoll Rand Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>), DexCom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), Monolithic Power Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>), Ameren Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>), GoDaddy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>), Mettler-Toledo International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>), MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), Eversource Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ES#NYSE">ES</a>), Hologic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>), Mohawk Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>), Camden Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPT#NYSE">CPT</a>) and Live Nation Entertainment Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>).
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45117801/apple-q2-earnings-preview-analysts-remain-bullish-with-caution-of-tariff-tornado-hitting-iphone">Apple Q2 Earnings Preview: Analysts Remain Bullish But Warn Of &#8216;Tariff Tornado&#8217; Hitting iPhone</a></li>
</ul>
Photo: Shutterstock

Government

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Economics

$BTC

ABNB

AMGN

CARR

SPDR Dow Jones Industrial Average ETF Trust

DXCM

EQIX

GDDY

HOLX

KLAC

MPWR

MSTR

QCOM

TEAM

Wall Street Eyes 8th Positive Day As S&P 500 Recoups Tariff-Led Losses, Bitcoin Rallies To $97,000: What's Driving Markets Thursday? (CORRECTED)

<a href="https://www.justice.gov/opa/media/1398796/dl" title="https://www.justice.gov/opa/media/1398796/dl">https://www.justice.gov/opa/media/1398796/dl</a>

EHTH

GOCO

SLQT

DOJ Says U.S. Alleges Aetna And Humana Each Conspired With Broker Defendants To Discriminate Against Medicare Beneficiaries With Disabilities; U.S Alleges Defendant Insurers Paid Hundreds Of Millions Of Dollars In Illegal Kickbacks To The Defendant Brokers

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) announced that&nbsp;CVS Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) CVS Caremark, a Pharmacy Benefit Manager (PBM), has decided that Wegovy&nbsp;(semaglutide) injection 2.4 mg will soon be the preferred&nbsp;GLP-1&nbsp;medicine on its largest commercial <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">template formularies</a>.
This change will take effect on July 1, 2025. 
&#8220;We believe in the unique benefits of Wegovy and the difference this medicine can make for patients seeking treatment,&#8221; said Dave Moore, executive vice president of U.S. Operations and president of Novo Nordisk Inc.
Independent of this formulary decision, Novo Nordisk will continue to <a target="_blank" href="https://www.prnewswire.com/news-releases/novo-nordisk-announces-that-cvs-caremark-the-countrys-largest-pbm-has-decided-wegovy-will-be-the-preferred-glp-1-medicine-covered-for-obesity-on-its-template-formularies-302443603.html" rel="noreferrer noopener">work</a> with CVS to identify additional ways to expand access to Wegovy&nbsp;for its customers.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/45019869/novo-nordisk-wins-legal-battle-to-curb-unsafe-knockoff-versions-of-ozempic-wegovy" rel="noreferrer noopener">Novo Nordisk Wins Legal Battle To Curb Unsafe Knockoff Versions Of Ozempic, Wegovy</a>
In February, the FDA confirmed that all doses of Wegovy were available. In March, Novo Nordisk launched NovoCare Pharmacy to provide direct-to-patient, convenient home shipments of all Wegovy dose strengths at a reduced cost of $499 per month for <a href="https://www.benzinga.com/25/03/44143391/novo-nordisk-boosts-wegovy-access-with-lower-pricing-and-home-delivery" target="_blank" rel="noreferrer noopener">self-paying patients</a>.
More recently, the Wegovy savings offer was updated, allowing eligible self-paying patients to get the $499-per-month price at their local pharmacy.
The FDA expanded the label in 2024 to include an indication for reduction of the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
On Tuesday, Novo Nordisk&nbsp;and&nbsp;Hims &amp; Hers Health, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) announced a&nbsp;<a target="_blank" href="https://www.benzinga.com/25/04/45074872/hims-hers-stock-surges-as-it-collaborates-with-novo-nordisk-to-sell-weight-loss-drug-wegovy-on-its-platform" rel="noreferrer noopener">long-term collaboration</a>.
The company said that at a single, unified price starting at $599 per month, individuals may be prescribed Wegovy. The offering is available this week on the Hims &amp; Hers platform.
This new offering builds on Hims &amp; Hers' existing suite of weight loss solutions and provides self-pay patients with access to all dose strengths of Wegovy in a high-quality pen.
Price Action: NVO stock is down 1.78% at $65.27 at the last check Thursday
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45136276/mounjaro-maker-eli-lilly-clocks-45-jump-in-q1-revenue-cuts-2025-profit-outlook-but-not-due-to-tariffs" target="_blank" rel="noreferrer noopener">Mounjaro Maker Eli Lilly Clocks 45% Jump In Q1 Revenue, Cuts 2025 Profit Outlook But Not Due To Tariffs</a></li>
</ul>
Photo: Shutterstock

Contracts

CVS Caremark To Place Novo Nordisk's Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment

U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Thursday.
Shares of CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) rose sharply during Thursday's session after the company reported better-than-expected first-quarter results and <a href="https://www.benzinga.com/quote/CVS/earnings">raised FY25 EPS guidance</a>.
CVS Health reported first-quarter sales of $94.59 billion on Thursday, beating the consensus of $93.64 billion. Total revenues increased 7% year over year, driven by revenue growth across all segments.
CVS Health posted adjusted EPS of $2.25 for Q1, a sharp rise from $1.31 a year earlier and well above Wall Street&#8217;s $1.70 estimate.
CVS Health shares jumped 6.5% to $71.11 on Thursday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Cantor Equity Partners, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEP#NASDAQ">CEP</a>) surged 28% to $53.98.</li>
<li>E2open Parent Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NASDAQ">ETWO</a>) shares jumped 26.4% to $2.4901.</li>
<li>CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) gained 24.4% to $4.6550 following better-than-expected quarterly earnings.</li>
<li>MediaAlpha, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAX#NYSE">MAX</a>) rose 19.7% to $10.06 following strong quarterly sales.</li>
<li>Lotus Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOT#NASDAQ">LOT</a>) gained 19.6% to $1.9500.</li>
<li>Advanced Energy Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEIS#NASDAQ">AEIS</a>) rose 16.7% to $113.72 after the company reported better-than-expected first-quarter financial results and issued second-quarter sales guidance above estimates. Additionally, Needham maintained a Buy rating on the stock and Baird maintained an Outperform rating.</li>
<li>MYR Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYRG#NASDAQ">MYRG</a>) gained 16.2% to $142.09 following upbeat quarterly earnings.</li>
<li>CONMED Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) rose 16.1% to $57.01 after the company reported better-than-expected first-quarter financial results and raised its FY25 guidance.</li>
<li>CoreWeave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) gained 15.3% to $47.60.</li>
<li>Chart Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) rose 14.2% to $154.11 after the company reported better-than-expected first-quarter adjusted EPS results and issued FY25 adjusted EPS guidance above estimates. Also, the company issued FY25 sales guidance with its midpoint above estimates.</li>
<li>TTM Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTMI#NASDAQ">TTMI</a>) gained 13.4% to $22.70 after the company reported better-than-expected first-quarter financial results and issued second-quarter guidance above estimates.</li>
<li>Frontdoor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTDR#NASDAQ">FTDR</a>) rose 13.3% to $46.56 after the company reported better-than-expected first-quarter financial results and raised tis FY25 sales guidance above estimates.</li>
<li>Quanta Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) gained 12.4% to $329.11 after the company reported better-than-expected first-quarter financial results and raised its FY25 guidance with its midpoint above estimates.</li>
<li>ATI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>) rose 12% to $60.87 after the company reported better-than-expected quarterly financial results and raised its FY25 adjusted EPS guidance.</li>
<li>Carrier Global Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) gained 10.4% to $69.07 after the company reported better-than-expected first-quarter financial results and raised its FY25 guidance.</li>
<li>Vertiv Holdings Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) rose 9.7% to $93.67.</li>
<li>Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) gained 9.6% to $433.29 following strong quarterly earnings.</li>
<li>MasTec, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) rose 8.2% to $137.75.</li>
<li>CNH Industrial N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNH#NYSE">CNH</a>) gained 8.2% to $12.52 following quarterly results.</li>
<li>Comfort Systems USA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) jumped 7.4% to $427.31.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) gained 6.4% to $260.16.</li>
<li>Hyatt Hotels Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) rose 6.2% to $119.61 following upbeat results.</li>
<li>Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) gained 5.6% to $580.00 following strong quarterly results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45135511/how-to-earn-500-a-month-from-apple-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Apple Stock Ahead Of Q2 Earnings</a> </li>
</ul>
Photo via Shutterstock

AEIS

CNMD

COMM

CRWV

CVNA

ETWO

FTDR

GTLS

MYRG

TTMI

CVS Health Posts Better-Than-Expected Earnings, Joins CommScope, Microsoft, Meta, Chart Industries, And Other Big Stocks Moving Higher On Thursday

CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) reported first-quarter sales of $94.59 billion on Thursday, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $93.64 billion</a>.
Total revenues increased 7% year over year, driven by revenue growth <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45128948/cvs-health-corporation-reports-first-quarter-2025-results-and-updates-full-year-2025-guidance" rel="noreferrer noopener">across all segments</a>.
CVS Health posted adjusted EPS of $2.25 for Q1, a sharp rise from $1.31 a year earlier and well above Wall Street's $1.70 estimate. The gain was primarily due to an increase in the Health Care Benefits segment's operating results, which reflects the favorable year-over-year impact of prior-year development and improved underlying performance in Medicare, including the impact of improved Medicare Advantage star ratings for the 2025 payment year.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44627279/ftc-pauses-lawsuit-against-cvs-cigna-unitedhealths-pbms-amid-commissioner-shortage" rel="noreferrer noopener">FTC Pauses Lawsuit Against CVS, Cigna, UnitedHealth's PBMs Amid Commissioner Shortage</a>
Adjusted operating income increased 54.9% to $4.58 billion, driven by increases across all operating segments.
Revenues in the Health Care Benefits segment increased 8% to $34.81 billion, primarily driven by increases in the Medicare product line, including the impact of improved Medicare Advantage star ratings for the 2025 payment year.
The Medical benefit ratio decreased from 90.4% to 87.3%, driven by the favorable year-over-year impact of prior-year development and improved underlying performance in Medicare, including the impact of improved Medicare Advantage star ratings for the 2025 payment year.
Medical membership as of March 31, 2025 of 27.1 million remained relatively consistent compared with December 31, 2024, reflecting membership declines in the individual exchange and Medicare product lines, which were largely offset by an increase in Commercial ASC membership.
Health Services segment (offering pharmacy benefit management) sales increased 7.9% to $43.46 billion, primarily driven by pharmacy drug mix, growth in specialty pharmacy, and brand inflation. These increases were partially offset by continued pharmacy client price improvements.
Pharmacy &amp; Consumer Wellness segment sales increased 11.1% to $31.91 billion, primarily driven by pharmacy drug mix and increased prescription volume. These increases were partially offset by continued pharmacy reimbursement pressure.
Prescriptions filled increased by 4.3%, and Same-store prescription volume increased by 6.7% in the quarter.
CVS Pharmacy is the first retail pharmacy in the NovoCare pharmacy network. This will enable CVS Pharmacy to provide eligible patients at its 9,000 community health locations with convenient, safe, and affordable access to Novo Nordisk A/S' (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy.
Guidance: CVS Health raises fiscal year 2025 adjusted EPS <a target="_blank" href="https://www.benzinga.com/25/02/43655820/cvs-health-stock-surges-on-better-than-expected-q4-earnings-upbeat-annual-outlook" rel="noreferrer noopener">from $5.75-$6.00</a> to $6.00-$6.20 versus consensus of $5.91.
The pharmacy retailer expects GAAP EPS of $4.23-$4.43, compared to the prior range of $4.58 to $4.83, and cash flow from operations guidance of approximately $7 billion.
Price Action:&nbsp;CVS stock is up 7.12% at $71.46 on last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45136276/mounjaro-maker-eli-lilly-clocks-45-jump-in-q1-revenue-cuts-2025-profit-outlook-but-not-due-to-tariffs" target="_blank" rel="noreferrer noopener">Mounjaro Maker Eli Lilly Clocks 45% Jump In Q1 Revenue, Cuts 2025 Profit Outlook But Not Due To Tariffs</a></li>
</ul>
Photo via Shutterstock

Guidance

CVS Health Partners With Wegovy Maker Novo Nordisk, Hikes 2025 Guidance

<ul>
<li>Wegovy will be the preferred GLP-1 medicine for obesity on the largest commercial template formularies for CVS Caremark, the largest Pharmacy Benefit Manager (PBM) in the US, effective July 1, 2025</li>
<li>Novo Nordisk is focused on new ways to drive access and affordability for Wegovy, the most widely prescribed and studied GLP-1 for weight loss that is fully available nationwide</li>
</ul>

Novo Nordisk Announced That CVS Caremark Has Decided That Wegovy (Semaglutide) Injection 2.4 Mg, The Most Widely Prescribed And Studied GLP-1 For Weight Loss, Will Soon Be The Preferred GLP-1 Medicine On Its Largest Commercial Template Formularies. This Change Will Be Effective July 1, 2025

Press Releases

CVS Health Foundation helps address barriers to care and provides resources for individuals with chronic health conditions in Hartford

CVS Weight Management™ Program Improves Health Outcomes While Also Lowering Costs

Dividends

CVS Health declares quarterly dividend

CVS Health to hold first quarter 2025 earnings conference call

CVS Health Announces Chief Financial Officer Transition Plan; Appoints Chief Medical Officer

CVS HEALTH CORPORATION REPORTS FIRST QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE

Glenview Capital Issues Statement on CVS Health

Legal

Kirby McInerney LLP Announces Investigation of Claims Against CVS Health Corporation (CVS) on Behalf of Investors

AM Best Affirms Credit Ratings of CVS Health Corporation's Aetna Inc. Subsidiaries

CVS Health celebrates reopening of Hendersonville store destroyed by Hurricane Helene

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

CVS Health

Unusual Options Activity for

뉴스

파트너 / 기고자

벤징가 글로벌

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
03:11 PMFeb 20, 2025	CALL	$50.00	Feb 21, 2025	-84	1412	350	19	7628	SWEEP	BEARISH
02:58 PMFeb 19, 2025	CALL	$52.50	Mar 21, 2025	-56	4	500	0	5506	TRADE	BULLISH
12:40 PMFeb 14, 2025	PUT	$65.00	Jan 16, 2026	245	2002	2000	35	5799	TRADE	BULLISH
09:37 AMFeb 13, 2025	CALL	$52.50	Jun 20, 2025	35	0	2950	0	4662	TRADE	NEUTRAL
09:35 AMFeb 13, 2025	CALL	$52.50	Jan 16, 2026	245	5003	5001	92	5445	TRADE	BEARISH
09:33 AMFeb 13, 2025	CALL	$47.50	Jan 16, 2026	245	4001	4000	93	4284	TRADE	BEARISH